Incyte, Hengrui In ‘Biggest Ever’ China Pharma Out-Licensing Deal
This article was originally published in PharmAsia News
Executive Summary
Incyte has acquired most global rights to an immuno-oncology antibody developed by China's Jiangsu Hengrui, in a deal worth up to nearly $800m plus royalties that will give the US firm a foothold in the PD-1 area and open up new combination therapies.
You may also be interested in...
Second Biogen/Eisai Antibody Moves AHEAD, In Asymptomatic Alzheimer’s
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Need a specific report? 1000+ reports available
Buy Reports